Priothera Ltd, a late-stage biopharma company developing a potential standard of care, mocravimod, in haematologic cancers, has appointed Hans Menssen to its board. A haematologist and oncologist, Dr Menssen most recently was senior global programme clinical head at Novartis Oncology and has held senior roles at Bayer Schering Pharma and Philogen SpA.
Copyright 2025 Evernow Publishing Ltd